Skip to content
Screener

NeoGenomics NEO Reportable Segment — Investment Income, Interest

Similar metrics at other companies

Indivior Pharmaceuticals, Inc. logo
INDVReportable Segment — Investment Income, Interest
$3M-25.0%
Zevra Therapeutics, Inc. logo
ZVRAReportable Segment — Investment Income, Interest
$1.48M-34.6%
SiTime Corporation logo
SITMReportable Segment — Investment Income, Interest
$12.55M+194%
BOB
BOBSReportable segment — Investment Income, Interest
$1.62M+514%
Claritev Corporation logo
CTEVReportable Segment — Investment Income, Interest
$195K-39.6%
Stitch Fix logo
SFIXReportable Segment — Investment Income, Interest
$2.12M-19.2%

Other financials

Income statement

See full
Revenue$201.7M+11.2%
Gross profit$91.9M+18.9%
Operating income-$9.8M+79.5%
Net income$2.2M+105%
EPS (diluted)$0.02+106%

Balance sheet

See full
Cash & equivalents$145.5M-5.9%
Total debt$448.4M+534%
Total equity$785.7M-8.0%
Total assets$1.4B-3.0%

Cash flow

See full
Operating cash flow$20.0M-1.8%
CapEx$8.2M+30.0%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$2.13B+184%
Enterprise value$2.43B+265%
P/S2.8×+1.7×

Profitability

See full
Gross margin43.9%0.0pp
Operating margin-8.9%-2.8pp
Net margin-6.8%-2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-6.3%-2.0pp
Debt / equity0.6×+0.5×
Current ratio3.6×-0.3×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001077183-26-000059
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Other sales and marketing(1)26,66623,21750,14244,927
Impairment charges20,04120,041
Loss from operations(9,771)(47,628)(28,012)(75,453)
Interest income1,2142,2632,4875,984
Interest expense(781)(933)(1,379)(2,551)
Other (expense) income(17)482(29)547
Gain on extinguishment of debt (Note 6)11,18111,181
Income (loss) before taxes1,826(45,816)(15,752)(71,473)

Item 1. Financial Statements (unaudited)

FAQ

What is NeoGenomics's reportable segment — investment income, interest?
NeoGenomics (NEO) reported reportable segment — investment income, interest of $1.21M in Q2 2026.
How has NeoGenomics's reportable segment — investment income, interest changed year-over-year?
NeoGenomics's reportable segment — investment income, interest decreased by 46.4% year-over-year, from $2.26M to $1.21M.
What is the long-term trend for NeoGenomics's reportable segment — investment income, interest?
Over 3 years (2022 to 2025), NeoGenomics's reportable segment — investment income, interest has grown at a 14.3% compound annual growth rate (CAGR), from $6.08M to $9.07M.
What does reportable segment — investment income, interest mean?
Income earned from cash balances, short-term investments, or other financial instruments held by the segment. This reflects the segment's ability to generate returns on its excess liquidity or cash reserves.

Ask your AI about NeoGenomics's reportable segment — investment income, interest.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude